Most Popular
-
1
Opposition-led Assembly unilaterally passes bill to probe Marine's death
-
2
Inflation eases in April, continues bumpy ride
-
3
Golden chance to liquidate babies’ gold rings?
-
4
Seoul to more than double military drones by 2026 to counter NK threats
-
5
On May Day, labor unions blast Yoon's foreign nanny proposal
-
6
[New faces of Assembly] Architect behind ‘audacious initiative’ believes in denuclearized North Korea
![[New faces of Assembly] Architect behind ‘audacious initiative’ believes in denuclearized North Korea](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/01/20240501050627_0.jpg&u=20240502093000)
-
7
Seoul alerts overseas missions to NK terror threats
-
8
Over 60% of S. Koreans support W100m childbirth incentive: survey
-
9
[KH Explains] Will alternative trading platform shake up Korean stock market?
![[KH Explains] Will alternative trading platform shake up Korean stock market?](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/01/20240501050557_0.jpg&u=20240501161906)
-
10
Russia sent more than 165,000 barrels of refined petroleum to N. Korea in March: White House
![[New faces of Assembly] Architect behind ‘audacious initiative’ believes in denuclearized North Korea](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/01/20240501050627_0.jpg&u=20240502093000)
![[KH Explains] Will alternative trading platform shake up Korean stock market?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/01/20240501050557_0.jpg&u=20240501161906)
Celltrion's Remsima logs record high sales in US in 2021
By YonhapPublished : Feb. 14, 2022 - 09:17
Sales of the biosimilar Remsima by Celltrion Inc. reached an all-time high last year in the United States, the company said Monday.
Sales of the biosimilar drug to treat autoimmune diseases jumped 13 percent on-year to $385 million in 2021, Celltrion Healthcare said, citing industry data.
Remsima references Janssen Biotech Inc.'s Remicade and is effective in treating various diseases, from rheumatoid arthritis to Crohn's disease.
Pharmaceutical giant Pfizer Inc. is responsible for sales of the biosimilar drug under the name Inflectra in the US market.
Remsima's market shares in the US came to 22.3 percent, trailing Remicade with 67.2 percent during the fourth quarter of last year, according to Celltrion Healthcare.
Sales of Remicade nearly halved over the last five years, plummeting from $4.5 billion in 2017 to $2 billion in 2021 following the launch of Remsima in the fourth quarter of 2016. (Yonhap)
